Cancer

Novartis International pharmaceutical
Biotech

For the first CAR-T therapy, early sales are weak but hopes are still sky high

By Damian Garde

In the Lab

Scientists create a biomedical tattoo to monitor for a sign of cancer

By Megan Thielking

Pharmalot

Pharmalittle: Shire sells cancer biz as Takeda circles; FDA does about-face on Alkermes drug

By Ed Silverman

Merck logo
Biotech

Merck extends its lead in immuno-oncology with ‘practice-changing’ lung cancer data

By Damian Garde

Melanoma tissue specimen
In the Lab

Scientists pinpoint a possible reason why melanoma doesn’t respond to cancer drugs

By Megan Thielking

Aspirin
In the Lab

Cancer surgery can awaken tumor cells, but in mice a cheap pill stops metastasis

By Sharon Begley

Pharmalot

Pharmalittle: Most Americans don’t know about cancer drug shortages; Ohio moves closer to ending gag clauses

By Ed Silverman

Cancer Chemotherapy
Pharmalot

Drug company payments appear to influence oncologists’ prescribing habits

By Ed Silverman

STAT Live

Archived: How is cancer science advancing patient care?

By STAT staff

Cancer in China
Biotech

Chinese patients get these cancers at an alarming rate. Now drug makers see an opportunity

By Rebecca Robbins

Merck logo
Pharmalot

With positive Keytruda data, Merck scrambles the market for lung cancer immunotherapies

By Ed Silverman

DNA testing materials
First Opinion

Consumers don’t need experts to interpret 23andMe genetic risk reports

By Anne Wojcicki

Biotech

Should Bristol-Myers panic over Incyte’s skin cancer failure?

By Damian Garde

The Readout LOUD

LISTEN: The FDA’s cold shoulder, the latest CAR-T contender, and how Grindr relates to personal genetics

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Empty medicine bottle
First Opinion

Unnecessary exclusions shut patients out of clinical trials

By David Gerber

Fecal micrograph Wargo
In the Lab

How gut bacteria impact cancer treatment: Meet the STAT Madness 2018 editors’ pick

By Eric Boodman

UCLA Central Campus
Pharma

Students push UCLA to improve access to a cancer drug developed by its scientists

By Elizabeth Cooney

Texas Medical Center in Houston
Biotech

Houston aspires to become the ‘third coast’ of biotech. Can it pull it off?

By Andrew Joseph

Duke cancer/stomach cells
In the Lab

Scientists find mini gastrointestinal tract growing inside tumor

By Meghana Keshavan

Video

CAR-T is a personalized attack on cancer. Here’s how it works

By Sharon Begley and Hyacinth Empinado

Jerome Adams & Lacey Adams
Health

Surgeon general’s wife treated for melanoma recurrence as he highlights risks of tanning

By Andrew Joseph

Wyss Immunotherapy - PLG Scaffold
In the Lab

Cancer immunotherapy implants get boost by Novartis licensing

By Elizabeth Cooney

Pharmalot

AbbVie lung cancer results are raising questions about a $6 billion deal

By Ed Silverman

Pharmalot

Pharmalittle: Roche ups the ante in lung cancer race; Chinese companies push further into U.S. generic market

By Ed Silverman

Checkpoint inhibitor
Health

Researchers puzzle over deadly heart condition tied to blockbuster cancer drugs

By Meghana Keshavan

Theranos
First Opinion

Getting past the bad blood of Theranos through collaboration

By Lauren Leiman and Seema Singh Bhan

Glowing Tumors
Health

Doctors hunt for hidden cancers with glowing dyes

By Associated Press

Pharmalot

Pharmalittle: Oregon has a new transparency law; former Glaxo CEO will now run a PBM

By Ed Silverman

Home saliva DNA test
First Opinion

At-home genetic testing may be convenient, but it isn’t complete

By Susan M. Domchek

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.